LC fluorescence method for multiple synthetic compounds to rapidly create in vivo pharmacokinetic database utilizing...

Area of Science:

• Pharmacokinetics and Drug Metabolism
• Analytical Chemistry
• Bioanalysis

Background:

• Accurate quantification of drug candidates in biological matrices is crucial for pharmacokinetic studies.
• Simultaneous analysis of multiple compounds can improve efficiency in drug discovery.
• Aryloxy-substituted aryl-piperazinyl derivatives (C1, C2, C3) are novel in-house molecules requiring pharmacokinetic evaluation.

Purpose of the Study:

• To develop and validate a robust bioanalytical method for simultaneous estimation of C1, C2, and C3 in rat serum.
• To determine the pharmacokinetic profiles of C1, C2, and C3 following intravenous administration.
• To compare pharmacokinetic data obtained from simultaneous (N-in-One) dosing versus individual dosing.

Main Methods:

• Development of a high-performance liquid chromatography (HPLC) assay with fluorescence detection (Ex: 250 nm, Em: 350 nm).
• Assay validation for linearity (12.5–400 ng/ml), accuracy, precision, and recovery in rat serum.
• Intravenous administration of a mixture of C1, C2, and C3 (N-in-One dosing) and individual compounds to rats, followed by serial blood sampling and analysis.

Main Results:

• The developed HPLC method demonstrated excellent linearity, accuracy, and precision within acceptable bioanalytical limits.
• Pharmacokinetic parameters were successfully determined for C1, C2, and C3 after both simultaneous and individual administrations.
• Results from N-in-One dosing correlated well with discrete dosing, validating the throughput-enhancing approach.

Conclusions:

• The validated HPLC assay provides a reliable method for simultaneous quantification of C1, C2, and C3 in rat serum.
• The N-in-One dosing strategy is an effective approach for accelerating pharmacokinetic data generation.
• Compound C2 exhibits favorable pharmacokinetic properties, suggesting its potential as a lead candidate.